Traditionally, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARBs) have been used to reduce the risk of kidney disease progression and CV complications in individuals with kidney disease and diabetes [13–15]. Here, ACE is linked to diabetes mellitus.